KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Net Margin (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Net Margin for 18 consecutive years, with 20.17% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin fell 653.0% year-over-year to 20.17%; the TTM value through Mar 2026 reached 29.65%, down 229.0%, while the annual FY2025 figure was 31.41%, 34.0% up from the prior year.
  • Net Margin hit 20.17% in Q1 2026 for Regeneron Pharmaceuticals, down from 21.74% in the prior quarter.
  • Across five years, Net Margin topped out at 1947.0% in Q1 2022 and bottomed at 20.17% in Q1 2026.
  • Average Net Margin over 5 years is 212.23%, with a median of 30.66% recorded in 2023.
  • Year-over-year, Net Margin skyrocketed 190290bps in 2022 and then tumbled -192114bps in 2023.
  • Regeneron Pharmaceuticals' Net Margin stood at 1197.1% in 2022, then plummeted by -97bps to 33.77% in 2023, then decreased by -28bps to 24.22% in 2024, then fell by -10bps to 21.74% in 2025, then decreased by -7bps to 20.17% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 20.17%, 21.74%, and 38.89% for Q1 2026, Q4 2025, and Q3 2025 respectively.